The bacteriophage T7 RNA polymerase gene was integrated into the fowlpox virus genome under the control of the vaccinia virus early/late promoter, P7.5-The recombinant fowlpox virus, fpEFLT7pol, stably expressed T7 RNA polymerase in avian and mammalian cells, allowing transient expression of transfected genes under the control of the T7 promoter. The recombinant fowlpox virus expressing T7 RNA polymerase offers an alternative to the widely used vaccinia virus vTF7-3, or the recently developed modified vaccinia virus Ankara (MVA) T7 RNA polymerase recombinant, a highly attenuated strain with restricted host-range. Recombinant fowlpox viruses have the advantage that as no infectious virus are produced from mammalian cells they do not have to be used under stringent microbiological safety conditions. Recombinant vaccinia viruses (rVV) have been produced expressing a variety of bacteriophage DNA-dependent RNA polymerases: T7 RNA polymerase (Fuerst et al., 1986) , T3 RNA polymerase (Rodriguez et al., 1990 ) and SP6 RNA polymerase (Usdin et al., 1993) . Cells infected with these rVVs can express biologically active products transiently from genes under the control of the appropriate RNA polymerase promoter. The most utilized system is an rVV expressing T7 RNA polymerase, vTF7-3. Translation of the T7 transcripts was inefficient, as only 5-10 % were capped, but inclusion of an internal ribosome entry signal (IRES) sequence, from encephalomyocarditis virus, at the 5' end of the T7-derived RNA transcripts, resulted in mRNAs that were CAP-independent and efficiently translated (Elroy-Stein et al., 1989).
Recombinant vaccinia viruses (rVV) have been produced expressing a variety of bacteriophage DNA-dependent RNA polymerases: T7 RNA polymerase (Fuerst et al., 1986) , T3 RNA polymerase (Rodriguez et al., 1990) and SP6 RNA polymerase (Usdin et al., 1993) . Cells infected with these rVVs can express biologically active products transiently from genes under the control of the appropriate RNA polymerase promoter. The most utilized system is an rVV expressing T7 RNA polymerase, vTF7-3. Translation of the T7 transcripts was inefficient, as only 5-10 % were capped, but inclusion of an internal ribosome entry signal (IRES) sequence, from encephalomyocarditis virus, at the 5' end of the T7-derived RNA transcripts, resulted in mRNAs that were CAP-independent and efficiently translated (Elroy-Stein et al., 1989) .
In addition to transient expression, a gene under the control of the T7 RNA polymerase promoter can also be integrated into the genome of a second rVV allowing high level expression of the gene product in cells dually infected with vTF7-3 and the second rVV (Fuerst et al., 1987) . The vTF7-3 system has been utilized for the expression of RNA per se, e.g. a defective RNA (D-RNA) of the coronavirus mouse hepatitis virus (MHV) was expressed from cDNA by vTF7-3 and used to repair a ts lesion in the genome of co-infected MHV by recombination (van der Most et al., 1992) . The vTF7-3 system has also been used to study replication of RNA viruses (Ball, 1994) and for the expression of complete RNA virus genomes from cDNAs leading to the production of viable rabies virus (Schnell et al., 1994) and vesicular stomatitis virus (Lawson et al., 1995) .
Vaccinia virus was the first eukaryotic virus to be successfully developed as a T7 RNA polymerase expression vector. However, an alternative system consisting of a recombinant baculovirus expressing T7 RNA polymerase has recently been produced (Polkinghorne & Roy, 1995) . The present paper describes the integration of the T7 RNA polymerase gene into the genome of fowlpox virus (FPV) and successful expression of T7 polymerase in avian and mammalian cells. Unlike VV, which belongs to the genus Orthopoxvirus and has a wide host range, FPV belongs to the genus Avipoxvirus and replicates only in avian species. In mammalian cells FPV replication is abortive with no evidence of production of infectious virus, though late CPE are observed at high m.o.i. (Somogyi et al., 1993) . The point at which replication is blocked appears to depend on cell type rather than on species. Early gene expression, genome replication and late gene expression occur in some cell types, with replication blocked during virion morphogenesis (Somogyi et aI., 1993) . Recombinant FPVs have been demonstrated to express foreign genes from VV 0001-3697 © 1996 SGM early/late promoters in mammalian cells and to induce protective immunity in mammals (Taylor et al., 1988) . Transient expression of foreign genes in both mammalian and avian cells using T7 RNA polymerase expressed from a rFPV would have several advantages. Firstly, the use of the recombinant FPV in mammalian cells would not result in production of any infectious FPV. Secondly, the biohazards and concomitant containment requirements would be considerably less than in the case of VV. Thirdly, rFPV would provide an alternative for dualinfection studies in which VV may interfere with the replication of the second virus.
T7 RNA polymerase recombinants were made from two FPV strains: FP9 (Mockett et al., 1992) , a plaquepurified isolate of HP438, itself derived from virulent isolate HP1 by 438 passages in chick embryo fibroblasts (CEFs); and Poxine, an embryo-derived vaccine strain (Duphar). The T7 RNA polymerase gene (EMBL/ GenBank accession no. M38308) was amplified from Sau3AI-and StuI-digested chromosomal DNA of E. coli 2 lysogen HMS174 (2DE3) (Novagen catalogue no. 69391-1) by PCR using oligonucleotides T7RNAPOL-1 (CGCGGATCCAGGCCTGAATTCACCATGAAC-ACGATTAACATCGC) and -2 (CGCGGATCCAGG-CCTGAATTCTTATTACGCGAACGCGAAGTCCG). T7RNAPOL-1 was designed so the T7 RNA polymerase initiation codon was in the context of an efficient Kozak sequence (Kozak, 1986 ) and T7RNAPOL-2 contained an extra translation termination codon. The T7 RNA polymerase gene PCR product (2.7 kbp) was ligated into pCR II (Invitrogen; TA vector), transformed into DH50~ cells (Gibco-BRL) and positive transformants identified by PCR (Britton et al., 1991) . Plasmids pT7POL-A4 and pT7POL-C1, containing the 2-7 kbp product from two independent PCRs, were sequenced using Sequenase (US Biochemical/Amersham). The 5' and 3' ends of the 2.7 kbp products corresponded to the T7 RNA polymerase gene (sequence data provided on request). However, 21 or 10 nucleotides had been deleted upstream of the sequences ACCATGAAC and GGCCTGAATT-CACCATGAAC in pT7POL-A4 and pT7POL-C1, respectively. The deletions did not affect the introduced Kozak sequence.
The T7 RNA polymerase gene was excised from pT7POL-A4 and -C1 using EcoRI, end-repaired, ligated into SmaI-cut pEFL29 (Qingzhong et al., 1994) , downstream of the VV early/late PT.s promoter and transformed into DH5~ cells, pEFL29 contains the lacZ gene, under the control of the FPV P4b promoter as a marker for recombinant viruses, and non-essential FPV sequences, flanking the PT.JSmaI region and the lacZ gene, to allow recombination of cloned genes into the FPV genome (Boursnell et al., 1990) . Transformants containing the T7 RNA polymerase gene were identified by colony hybridization using a 32P-labelled PCR product derived from the T7 RNA polymerase gene and were sequenced using oligonucleotides T7RNAPOL-2 and FPOXINS-1 (CATAAATAATAAATACAATAA-TTA). The T7 RNA polymerase gene was found to be in the correct orientation for expression from the VV P7.5 promoter in plasmids pEFLT7PolA4-3 and pEFLT7PolCI-6 and the 5' and 3' ends of the genes were intact. However, pEFLT7PolC1-6 was five nucleotides shorter in the region between the VV PT.s promoter and the initiation codon of the T7 polymerase gene, resulting from the extra EcoRI site in the linker sequence of pT7POL-C1.
To determine whether plasmids pEFLT7PolA4-3 and pEFLT7PolC1-6 expressed T7 RNA polymerase, they were co-transfected with plasmid pT7dDIIImsGOC (Percy et al., 1992 ; a gift from D. Stone, University of Reading, UK), using Lipofectin (Gibco-BRL), into CEF cells infected with either FPV or VV. Plasmid pT7dDIIImsGOC contains: the T7 promoter followed by the reporter gene fl-glucuronidase, a modified 5' noncoding region of poliovirus (containing the IRES) and the reporter gene chloramphenicol acetyltransferase (CAT). CAT would be expressed from pT7dDIIImsGOC by T7 RNA polymerase produced from either pEFLT7PolA4-3 or pEFLT7PolC1-6. Cell extracts from the transfected cells infected with either wild-type FPV or VV were assayed for CAT activity using acetyl coenzyme-A and D-threo-[dichloroacetyl-l-14C] chloramphenicol. Both plasmids resulted in the expression of CAT but pEFLT7PolC1-6 produced more CAT activity than pEFLT7PolA3-4 and was therefore used subsequently.
Recombinant FPVs (rFPV), containing the T7 RNA polymerase gene, were produced by recombination between pEFLT7PolC1-6 and either the FP9 or Poxine strain of FPV in CEF cells. Potential rFPVs were analysed for expression of T7 RNA polymerase in CEF cells using pT7dDIIImsGOC. At 22 h post-infection (p.i.) the cells were lysed and assayed for CAT protein by CAT ELISA (Boehringer Mannheim). Three rFPVs were identified that expressed CAT protein (Table 1) , one derived from FP9 and two from Poxine. The FP9-derived rFPV, fpEFLT7Pol/FP9, was used for subsequent experiments due to the fact FP9 grows to higher titres in tissue culture than does the Poxine strain.
Transient expression studies in CEF cells confirmed that fpEFLT7Pol/FP9 expressed T7 RNA polymerase. We wished to determine whether a mammalian cell line, Vero cells (ATCC CCL81), infected with fpEFLT7Pol/ FP9 would produce T7 RNA polymerase, to determine the activity of the polymerase throughout the rFPV replication cycle and to compare expression of the polymerase with that from vTF7-3. Cell extracts from Table 1 . Analysis of rFPV for expression of T7 RNA polymerase CEF cells were infected with vTF7-3 or potential rFPVs, derived from either FP9 or Poxine, and produced using the T7 RNA polymerase containing plasmid pEFLT7PolC1-6. Vero cells infected with fpEFLT7Pol/FP9 or vTF7-3, taken at 4-hourly intervals p.i., were assayed for T7 RNA polymerase activity. A linearized DNA template containing a T7 promoter was used for the synthesis of RNA, by the T7 RNA polymerase, as measured by the incorporation of [~-~2P]CTP according to the method of Fuerst et al. (1986) , except that 2 lal out of 150 pl of cell extract was assayed using 0-1 MBq [ct-32P]CTP (111 TBq/mmol, NEG-008H, DuPont). As can be seen from Fig. 1 , T7 RNA polymerase activity was detectable in extracts of cells infected with fpEFLT7Pol/FP9 from 8 h p.i. and with vTF7-3 from 12 h p.i., with higher activities later in the replication cycles. The higher levels of T7 RNA polymerase activity observed later in the replication cycles of fpEFLT7Pol/FP9 and VV were either due to accumulation of the polymerase or to higher levels of late expression from the VV PT.~ promoter, or a combination of these two effects. In the presence of 401ag/ml araC (1-fl-o-arabinofuranosylcytosine), used to inhibit poxvirus late gene expression, expression of the T7 RNA polymerase by fpEFLT7Po]/ FP9 did not increase after 8 h p.i. (data not shown), in agreement with the observation for the expression of T7 RNA polymerase from vTF7-3 in CV-1 cells (Fuerst et al., 1987) . This observation indicated that T7 RNA polymerase activity seen late in infection was due to de novo late gene expression. CAT was also transiently expressed from pT7dDIIImsGOC in Vero cells using either fpEFLT7Pol/FP9 or vTF7-3 to demonstrate that the rFPV system could be used for transient expression in mammalian cells. As can be seen from Table 2 there was no significant difference in the transient expression of CAT using either system. In summary, we have produced a rFPV, fpEFLT7Pol/ FP9, that expresses bacteriophage T7 RNA polymerase in mammalian as well as avian cells. Transfection of cells, previously infected with fpEFLT7Pol/FP9, with a plasmid containing a reporter gene under the control of a T7 promoter, resulted in transient expression of the gene in both CEF and Vero cells. The levels of expression of T7 RNA polymerase and transient expression of a reporter gene were comparable to those observed for vTF7-3. Preliminary data indicate that the optimal time for transfection is 5 h p.i. using the rFPV at an m.o.i, of 3 (S. Kottier, unpublished). Although we only characterized the FP9-derived rFPV we believe that the Poxinederived rFPV should have the same characteristics as it was also produced using pEFLT7PolC1-6 (Table 1 ). The advantage of the Poxine-derived rFPV over the tissue culture-adapted, FP9-derived rFPV is that it should be better for expression in vivo in chicken.
Amount of CAT
A major disadvantage of the VV system is the CPE, due to the replication of VV, which may interfere with the production/detection of the product in the particular study. This is particularly important in studies that involve co-infection of the VV-infected cells with a second virus. Other factors associated with co-infection experiments are: (1) the presence of VV in the cells may render them refractory to infection with the second virus; (2) the production and subsequent release of progeny VV. These additional factors may either preclude the use of the VV T7 system or require methods to remove the VV from the progeny viruses. T7 RNA polymerase rFPVs have several advantages over the use of equivalent rVVs: (1) FPV is able to infect mammalian cells for the expression of foreign genes but without the concomitant production of infectious virus particles; (2) FPV only causes CPE late in infection and at high m.o.i. ; (3) FPV has a longer replication cycle allowing an increased time for the synthesis of foreign gene products; (4) the use of fowlpox virus does not require stringent microbiological safety requirements as it is not classified as a human pathogen. Although we routinely use primary CEFs for growth of FPV it can be propagated and plaqued (P. Green & M.A. Skinner, unpublished) in a transformed quail cell line (QT35; Moscovici et aI., 1977) .
The T7 RNA polymerase rFPV, together with the recently developed T7 RNA polymerase recombinants of the restricted host-range MVA strain of VV (Wyatt et al., 1995; Sutter et al., 1995) , provides both an additional tool and an alternative to vTF7-3 for transient expression allowing study of RNA or protein products, The rFPV described here has the T7 RNA polymerase under control of the VV P7.5 early/late promoter, as in the MVA recombinant by Sutter et al. (1995) and in vTF7-3. In the other MVA recombinant (Wyatt et al., 1995) it is under control of the VV Ptl late promoter. Thus T7 RNA polymerase can now be delivered and expressed in a number of ways to suit the target cell and the needs of the particular experiment.
